Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Ovarian Neoplasms 1Leukemia, Myeloid, Chronic-Phase 1

Interventions

Peripheral Blood Stem Cell Transplantation 11Mycophenolic Acid 8Cyclosporine 8fludarabine phosphate 7Imatinib Mesylate 6Busulfan 5Tacrolimus 4Radiotherapy 4Methotrexate 4Cyclophosphamide 4nilotinib 3bosutinib 3Whole-Body Irradiation 3Cord Blood Stem Cell Transplantation 3Antilymphocyte Serum 3Melphalan 2Filgrastim 2Dasatinib 2Cytarabine 2Alemtuzumab 2sargramostim 1ruxolitinib 1ponatinib 1montanide ISA 51 1liposomal doxorubicin 1ethanolamine oleate 1avelumab 1atezolizumab 1aldesleukin 1Vorinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Leukemia, Myeloid, Chronic-Phase × Tyrosine Kinase Inhibitors × Clear all
NCT04006847 2022-07-01

Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Milton S. Hershey Medical Center

Phase 1/2 Terminated
1 enrolled 5 charts
Other hematologic neoplasm

Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡